<DOC>
	<DOCNO>NCT00049322</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , cisplatin , mitomycin , work different way stop growth cancer cell , either kill cell stop cell divide . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . Monoclonal antibody , bevacizumab , kill tumor cell leave chemoembolization block ability grow spread . PURPOSE : This randomized phase II trial study see chemoembolization follow bevacizumab work well chemoembolization alone treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Chemoembolization Bevacizumab Treating Patients With Liver Cancer That Can Be Removed With Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare neovessel formation 8 14 week hepatic arterial chemoembolization patient unresectable hepatocellular carcinoma treat bevacizumab versus bevacizumab ( observation chemoembolization ) . - Compare time progression , objective response rate , tumor marker progression patient treat regimen . - Determine pharmacokinetics bevacizumab patient liver function impairment . - Determine toxic effect drug patient . - Compare cancer biomarker pattern peripheral blood cell plasma chemoembolization patient treat regimen . OUTLINE : This randomize , open-label study . All patient receive hepatic artery chemotherapy ( chemoembolization ) comprise doxorubicin HCl liposome , cisplatin , mitomycin day 8 possibly day 92 . Patients randomize 1 2 treatment arm . - Arm I : Patients receive bevacizumab IV 30-90 minute every 2 week begin 1 week prior first chemoembolization . Courses repeat every 2 week absence disease progression unacceptable toxicity . - Arm II : Patients receive bevacizumab . Patients arm II may cross-over receive bevacizumab arm I recurrent tumor evident week 14 CT scan MRI 50 % great increase AFP level occur since day 8 chemoembolization . PROJECTED ACCRUAL : A total 30 patient ( 15 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; 18 year old Histologically cytologically document HCC Patients must bidimensional measurable disease CT MRI scan exceed 50 % liver parenchyma Patients must consider clinical candidate chemoembolization , least one lesion &gt; 3cm lesion &gt; 15cm long diameter Patients await cadaveric orthotopic liver transplantation eligible meet criterion . These patient must model endstage liver disease priority score &lt; 28 point entry Cirrhosis ChildPugh class A B Patients document grad III varix prior history UGI bleeding require endoscopic evaluation prior treatment protocol . Platelet count equal great 60,000/μL Female patient must use effective contraception , surgically sterile postmenopausal ; male patient must use barrier contraception surgically sterile Patients must willing able comply study requirement sign informed consent Previous history liver transplantation Fibrolamellar histology Prior antiangiogenesis therapy Presence extrahepatic disease Presence biliary obstruction define biliary dilatation total bilirubin &gt; 2.5mg/dl Thrombosis main portal vein Absolute contraindication doxorubicin , mitomycinC , cisplatin , iodinate contrast material , Avitene dexamethasone treatment Other active malignancy past year ( except nonmelanoma skin cancer situ carcinoma ) ECOG PS &gt; 2 life expectancy &lt; 12 week History evidence upon physical examination CNS disease Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure within 3 month study entry ; fine needle aspiration within 7 day prior Day 0 Current recent ( within 10 day prior Day 0 ) use fulldose oral parenteral anticoagulant ( except require maintain patency preexisting , permanent indwell IV catheter ) thrombolytic agent ( subject receive warfarin , international normalized ration &lt; 1.5 ) Chronic , daily treatment aspirin ( &gt; 325mg/day ) nonsteroidal antiinflammatory medication Positive pregnancy test lactation Proteinuria baseline clinically significant impairment renal function . Subjects unexpectedly discover &gt; 1+ proteinuria baseline undergo 24hour urine collection , must adequate collection must demonstrate &lt; 500 mg protein/24 hr allow participation study Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Current recent ( within 28 day prior Day 0 ) participation another experimental drug study Clinically significant cardiovascular disease , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 1 year prior Day 0 Prior history hypertensive crisis hypertensive encephalopathy History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 Significant vascular disease within 6 month prior Day 1 Screening clinical laboratory value : ANC &lt; 1500/μL INR &gt; 1.5 Total bilirubin &gt; 2.5mg/dL AST ALT &gt; 5 time upper limit normal Serum creatinine &gt; 2.0 mg/dL creatinine clearance &lt; 45 mL/min Hemoglobin &lt; 8.5 gm/dL History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>